CY1113622T1 - Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης - Google Patents
Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινηςInfo
- Publication number
- CY1113622T1 CY1113622T1 CY20121101168T CY121101168T CY1113622T1 CY 1113622 T1 CY1113622 T1 CY 1113622T1 CY 20121101168 T CY20121101168 T CY 20121101168T CY 121101168 T CY121101168 T CY 121101168T CY 1113622 T1 CY1113622 T1 CY 1113622T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fluorophenoxymethyl
- piperidine
- phenyl
- compound
- crystalline form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Η εφεύρεση παρέχει ένα κρυσταλλικό υδροχλωρικό άλας της 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδίνης. Η εφεύρεση αυτή παρέχει επίσης φαρμακευτικές συνθέσεις οι οποίες περιέχουν το κρυσταλλικό άλας, διαδικασίες και ενδιάμεσες ενώσεις για την παρασκευή του κρυσταλλικού άλατος και μεθόδους για τη χρήση του κρυσταλλικού άλατος για τη θεραπευτική αντιμετώπιση νόσων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11454108P | 2008-11-14 | 2008-11-14 | |
EP09752988A EP2358676B1 (en) | 2008-11-14 | 2009-11-13 | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113622T1 true CY1113622T1 (el) | 2016-06-22 |
Family
ID=41666409
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121101168T CY1113622T1 (el) | 2008-11-14 | 2012-11-29 | Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης |
CY20121101189T CY1113623T1 (el) | 2008-11-14 | 2012-12-07 | Ενωσεις 4-[2-(2-φθοροφαινοξυμεθυλ)φαινυλ]πιπεριδινης |
CY20131100256T CY1113855T1 (el) | 2008-11-14 | 2013-03-26 | Διεργασια για την παρασκευη ενωσεων 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121101189T CY1113623T1 (el) | 2008-11-14 | 2012-12-07 | Ενωσεις 4-[2-(2-φθοροφαινοξυμεθυλ)φαινυλ]πιπεριδινης |
CY20131100256T CY1113855T1 (el) | 2008-11-14 | 2013-03-26 | Διεργασια για την παρασκευη ενωσεων 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης |
Country Status (29)
Country | Link |
---|---|
US (23) | US8247433B2 (el) |
EP (3) | EP2358676B1 (el) |
JP (6) | JP5598798B2 (el) |
KR (3) | KR101685186B1 (el) |
CN (3) | CN102209712B (el) |
AR (3) | AR074128A1 (el) |
AU (3) | AU2009313948B2 (el) |
BR (3) | BRPI0921595B8 (el) |
CA (3) | CA2742114C (el) |
CL (2) | CL2011001088A1 (el) |
CO (2) | CO6361988A2 (el) |
CY (3) | CY1113622T1 (el) |
DK (3) | DK2358674T3 (el) |
ES (3) | ES2401224T3 (el) |
HK (3) | HK1160449A1 (el) |
HR (3) | HRP20120897T1 (el) |
IL (2) | IL212230A (el) |
MX (3) | MX2011005088A (el) |
MY (2) | MY151211A (el) |
NZ (2) | NZ592413A (el) |
PL (3) | PL2358676T3 (el) |
PT (3) | PT2358675E (el) |
RU (2) | RU2503662C2 (el) |
SG (1) | SG171311A1 (el) |
SI (3) | SI2358676T1 (el) |
SM (3) | SMT201200063B (el) |
TW (3) | TWI461407B (el) |
WO (3) | WO2010056938A1 (el) |
ZA (1) | ZA201103495B (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010056938A1 (en) | 2008-11-14 | 2010-05-20 | Theravance, Inc. | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
EP2523945A1 (en) * | 2010-01-11 | 2012-11-21 | Theravance, Inc. | 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors |
US8530663B2 (en) * | 2010-03-22 | 2013-09-10 | Theravance, Inc. | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
US20110263631A1 (en) * | 2010-04-22 | 2011-10-27 | Martin William J | Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain |
US9115133B2 (en) | 2011-03-22 | 2015-08-25 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
US9544692B2 (en) * | 2012-11-19 | 2017-01-10 | Bitwave Pte Ltd. | System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability |
MX370970B (es) * | 2016-08-30 | 2020-01-10 | Theravance Biopharma R&D Ip Llc | Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. |
ES2960492T3 (es) * | 2018-06-01 | 2024-03-05 | Theravance Biopharma R&D Ip Llc | Procedimiento para la preparación de ácido 2-(1-(terc-butoxicarbonil)piperidín-4-il)benzoico |
TW202345817A (zh) | 2022-03-28 | 2023-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 治療患有多系統萎縮之個體的方法 |
CN114957098B (zh) * | 2022-06-02 | 2024-03-29 | 和鼎(南京)医药技术有限公司 | 一种制备喷他佐辛中间体的方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
DE2549999A1 (de) * | 1975-11-07 | 1977-05-12 | Boehringer Mannheim Gmbh | Piperidin-derivate und verfahren zu ihrer herstellung |
US4241071A (en) | 1977-01-27 | 1980-12-23 | American Hoechst Corporation | Antidepressant (α-phenyl-2-tolyl)azacycloalkanes |
IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
EP0190496A3 (en) | 1984-12-13 | 1987-05-27 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
DE3835291A1 (de) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
GB9324018D0 (en) * | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
AU4637899A (en) * | 1998-07-10 | 2000-02-01 | Astrazeneca Ab | N-substituted naphthalene carboxamides as neurokinin-receptor antagonists |
GB9922521D0 (en) | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
ES2157148B1 (es) * | 1998-11-18 | 2002-03-01 | Faes Fabrica Espanola De Produ | Nuevas piperidinas 4-sustituidas. |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
CZ20013424A3 (cs) * | 1999-12-27 | 2002-02-13 | Japan Tobacco Inc. | Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva |
US6630504B2 (en) * | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
US7294637B2 (en) * | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
WO2004017977A2 (en) * | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
UA81469C2 (en) * | 2003-04-04 | 2008-01-10 | Lundbeck & Co As H | 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
JP2006522027A (ja) * | 2003-04-04 | 2006-09-28 | ハー・ルンドベック・アクチエゼルスカベット | セロトニン再取り込み阻害剤としての4−(2−フェニルオキシフェニル)−ピペリジンまたは−1,2,3,6−テトラヒドロピリジン誘導体 |
WO2004110995A1 (en) * | 2003-06-17 | 2004-12-23 | Pfizer Limited | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
TW200513461A (en) | 2003-10-01 | 2005-04-16 | Speedel Experimenta Ag | Organische verbindungen |
US20070105870A1 (en) * | 2004-01-13 | 2007-05-10 | Pfizer Inc. | Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors |
US20070072859A1 (en) * | 2004-03-05 | 2007-03-29 | Eli Lilly And Company | Pharmaceutical compounds |
BRPI0510453A (pt) * | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
GB0505437D0 (en) * | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
US20070142389A1 (en) * | 2005-12-20 | 2007-06-21 | Pfizer Inc. | Piperidine derivatives |
US20070249607A1 (en) * | 2006-04-17 | 2007-10-25 | Bristol-Myers Squibb Company | Nk-1 and serotonin transporter inhibitors |
WO2008023258A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
WO2008039418A2 (en) * | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor modulators |
US8026257B2 (en) * | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
WO2010008739A2 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
WO2010011811A2 (en) | 2008-07-24 | 2010-01-28 | Theravance, Inc. | 3-(phenoxyphenylmethyl)pyrrolidine compounds |
WO2010056938A1 (en) * | 2008-11-14 | 2010-05-20 | Theravance, Inc. | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
EP2523945A1 (en) | 2010-01-11 | 2012-11-21 | Theravance, Inc. | 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors |
US8530663B2 (en) * | 2010-03-22 | 2013-09-10 | Theravance, Inc. | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
MX370970B (es) * | 2016-08-30 | 2020-01-10 | Theravance Biopharma R&D Ip Llc | Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. |
-
2009
- 2009-11-13 WO PCT/US2009/064304 patent/WO2010056938A1/en active Application Filing
- 2009-11-13 KR KR1020117013185A patent/KR101685186B1/ko active IP Right Grant
- 2009-11-13 PT PT97526883T patent/PT2358675E/pt unknown
- 2009-11-13 MX MX2011005088A patent/MX2011005088A/es active IP Right Grant
- 2009-11-13 CN CN200980144708.1A patent/CN102209712B/zh active Active
- 2009-11-13 SI SI200930419T patent/SI2358676T1/sl unknown
- 2009-11-13 RU RU2011123890/04A patent/RU2503662C2/ru active
- 2009-11-13 TW TW098138704A patent/TWI461407B/zh active
- 2009-11-13 CN CN200980145228.7A patent/CN102216272B/zh active Active
- 2009-11-13 TW TW098138705A patent/TWI441810B/zh active
- 2009-11-13 PT PT97529887T patent/PT2358676E/pt unknown
- 2009-11-13 KR KR1020117013512A patent/KR101656338B1/ko active IP Right Grant
- 2009-11-13 CA CA2742114A patent/CA2742114C/en active Active
- 2009-11-13 ES ES09752687T patent/ES2401224T3/es active Active
- 2009-11-13 US US12/617,845 patent/US8247433B2/en active Active
- 2009-11-13 BR BRPI0921595A patent/BRPI0921595B8/pt active IP Right Grant
- 2009-11-13 AU AU2009313948A patent/AU2009313948B2/en active Active
- 2009-11-13 TW TW098138707A patent/TWI443087B/zh active
- 2009-11-13 DK DK09752687.5T patent/DK2358674T3/da active
- 2009-11-13 DK DK09752988.7T patent/DK2358676T3/da active
- 2009-11-13 US US12/617,821 patent/US8304432B2/en active Active
- 2009-11-13 MY MYPI20111925 patent/MY151211A/en unknown
- 2009-11-13 DK DK09752688.3T patent/DK2358675T3/da active
- 2009-11-13 ES ES09752688T patent/ES2396583T3/es active Active
- 2009-11-13 EP EP09752988A patent/EP2358676B1/en active Active
- 2009-11-13 JP JP2011536490A patent/JP5598798B2/ja active Active
- 2009-11-13 CN CN2009801452272A patent/CN102216271B/zh active Active
- 2009-11-13 AR ARP090104419A patent/AR074128A1/es active IP Right Grant
- 2009-11-13 PL PL09752988T patent/PL2358676T3/pl unknown
- 2009-11-13 NZ NZ592413A patent/NZ592413A/xx not_active IP Right Cessation
- 2009-11-13 EP EP09752688.3A patent/EP2358675B9/en active Active
- 2009-11-13 RU RU2011123875/04A patent/RU2515612C2/ru active
- 2009-11-13 PT PT97526875T patent/PT2358674E/pt unknown
- 2009-11-13 PL PL09752688T patent/PL2358675T3/pl unknown
- 2009-11-13 ES ES09752988T patent/ES2397247T3/es active Active
- 2009-11-13 KR KR1020117013510A patent/KR101656339B1/ko active IP Right Grant
- 2009-11-13 MY MYPI20111690 patent/MY151229A/en unknown
- 2009-11-13 EP EP09752687A patent/EP2358674B1/en active Active
- 2009-11-13 WO PCT/US2009/064306 patent/WO2010056939A1/en active Application Filing
- 2009-11-13 SI SI200930543T patent/SI2358674T1/sl unknown
- 2009-11-13 JP JP2011536491A patent/JP5506813B2/ja active Active
- 2009-11-13 MX MX2011005090A patent/MX2011005090A/es active IP Right Grant
- 2009-11-13 AR ARP090104418A patent/AR074350A1/es not_active Application Discontinuation
- 2009-11-13 SI SI200930435T patent/SI2358675T1/sl unknown
- 2009-11-13 CA CA2742105A patent/CA2742105C/en active Active
- 2009-11-13 BR BRPI0921593A patent/BRPI0921593B8/pt active IP Right Grant
- 2009-11-13 MX MX2011005089A patent/MX2011005089A/es active IP Right Grant
- 2009-11-13 PL PL09752687T patent/PL2358674T3/pl unknown
- 2009-11-13 CA CA2739992A patent/CA2739992C/en active Active
- 2009-11-13 BR BRPI0921596-4A patent/BRPI0921596B1/pt active IP Right Grant
- 2009-11-13 AU AU2009313951A patent/AU2009313951B2/en active Active
- 2009-11-13 SG SG2011035169A patent/SG171311A1/en unknown
- 2009-11-13 NZ NZ592543A patent/NZ592543A/xx unknown
- 2009-11-13 JP JP2011536493A patent/JP5529150B2/ja active Active
- 2009-11-13 AU AU2009313949A patent/AU2009313949B2/en not_active Ceased
- 2009-11-13 WO PCT/US2009/064308 patent/WO2010056941A1/en active Application Filing
- 2009-11-13 US US12/617,838 patent/US8304433B2/en active Active
-
2011
- 2011-04-10 IL IL212230A patent/IL212230A/en active IP Right Grant
- 2011-04-26 IL IL212452A patent/IL212452A0/en active IP Right Grant
- 2011-05-09 CO CO11056556A patent/CO6361988A2/es active IP Right Grant
- 2011-05-12 CL CL2011001088A patent/CL2011001088A1/es unknown
- 2011-05-12 ZA ZA2011/03495A patent/ZA201103495B/en unknown
- 2011-05-13 CL CL2011001093A patent/CL2011001093A1/es unknown
- 2011-05-25 CO CO11064614A patent/CO6361993A2/es active IP Right Grant
-
2012
- 2012-01-26 HK HK12100743.6A patent/HK1160449A1/xx not_active IP Right Cessation
- 2012-01-26 HK HK12100742.7A patent/HK1160448A1/xx unknown
- 2012-01-27 HK HK12100779.3A patent/HK1160452A1/xx unknown
- 2012-07-10 US US13/545,513 patent/US8802857B2/en active Active
- 2012-09-28 US US13/631,192 patent/US8604058B2/en active Active
- 2012-10-01 US US13/632,588 patent/US8592596B2/en active Active
- 2012-11-07 HR HRP20120897AT patent/HRP20120897T1/hr unknown
- 2012-11-13 HR HRP20120920AT patent/HRP20120920T1/hr unknown
- 2012-11-29 CY CY20121101168T patent/CY1113622T1/el unknown
- 2012-12-07 CY CY20121101189T patent/CY1113623T1/el unknown
- 2012-12-27 SM SM201200063T patent/SMT201200063B/it unknown
- 2012-12-28 SM SM201200065T patent/SMT201200065B/xx unknown
-
2013
- 2013-03-26 CY CY20131100256T patent/CY1113855T1/el unknown
- 2013-03-26 SM SM201300033T patent/SMT201300033B/xx unknown
- 2013-04-02 HR HRP20130300AT patent/HRP20130300T1/hr unknown
- 2013-10-23 US US14/060,846 patent/US9073859B2/en active Active
- 2013-11-04 US US14/070,887 patent/US9162982B2/en active Active
-
2014
- 2014-02-25 JP JP2014033727A patent/JP2014098033A/ja not_active Withdrawn
- 2014-03-07 JP JP2014044653A patent/JP2014101384A/ja not_active Withdrawn
- 2014-03-12 JP JP2014048387A patent/JP2014139209A/ja not_active Withdrawn
- 2014-07-08 US US14/325,863 patent/US9187423B2/en active Active
-
2015
- 2015-06-02 US US14/728,079 patent/US20160022660A1/en not_active Abandoned
- 2015-09-09 US US14/848,933 patent/US9675599B2/en active Active
-
2017
- 2017-05-04 US US15/586,531 patent/US10226454B2/en active Active
- 2017-05-10 US US15/591,419 patent/US10034870B2/en active Active
-
2018
- 2018-06-13 US US16/007,233 patent/US10206913B2/en active Active
-
2019
- 2019-01-03 US US16/239,265 patent/US10441579B2/en active Active
- 2019-01-10 US US16/244,956 patent/US10576073B2/en active Active
- 2019-06-11 AR ARP190101607A patent/AR114965A2/es unknown
- 2019-09-04 US US16/559,928 patent/US10722504B2/en active Active
-
2020
- 2020-01-16 US US16/744,551 patent/US10946006B2/en active Active
- 2020-06-17 US US16/903,579 patent/US10946007B2/en active Active
-
2021
- 2021-02-03 US US17/248,692 patent/US11723900B2/en active Active
- 2021-02-05 US US17/248,737 patent/US11596624B2/en active Active
-
2023
- 2023-02-28 US US18/115,436 patent/US20230201181A1/en active Pending
-
2024
- 2024-02-16 US US18/443,907 patent/US20240316024A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113622T1 (el) | Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης | |
CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
CY1124622T1 (el) | Μεθοδοι θεραπειας του καρκινου με τη χρηση 3-(4-((4-(μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο- 2,6-διονης | |
CY1118621T1 (el) | Πολυμορφικες μορφες του 2-(5-βρωμο-4-(4-κυκλο προπυλναφθαλιν-1-υλ)-4η-1,2,4-τριαζολ-3-υλθειο) οξικου οξεος και χρησεις αυτων | |
CY1117978T1 (el) | Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a | |
CY1121592T1 (el) | Μια στερεη μορφη της υδροχλωρικης (s)-3-(4-((4-μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο-2,6-διονης | |
CY1119488T1 (el) | Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου | |
CY1109072T1 (el) | Βητα κρυσταλλικη μορφη του υδροχλωρικου αλατος της ιβαμπραδινης, μεθοδος παρασκευης αυτου και φαρμακευτικης συνθεσεις που το περιεχουν | |
CY1114637T1 (el) | 4-[4-({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλο)]καρβαμοϋλ}αμινο)-3-φθοροφαινοξυ]-ν-μεθυλοπυριδινο-2-καρβοξαμιδιο μονοϋδρικο | |
CY1123426T1 (el) | Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος | |
EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
CY1112558T1 (el) | Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους | |
CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
EA201270546A1 (ru) | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ | |
CY1117962T1 (el) | Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης | |
CY1111275T1 (el) | Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου | |
NO20090250L (no) | Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte | |
NO20082209L (no) | Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer | |
CY1112366T1 (el) | Ενωσεις βενζιμιδαζολης- καρβοξαμιδης ως αγωνιστες του 5-ητ4 υποδοχεα | |
RS53138B (en) | 4- [2- (4-METHYLPHENYLSULPHANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF INJURED INTENTION SYNDROME (IBS). | |
EA201200868A1 (ru) | Ингибиторы диацилглицеролацилтрансферазы | |
EA200600760A1 (ru) | Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их | |
NO20076396L (no) | Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette | |
EA201000613A1 (ru) | Тризамещенные пиперидины | |
EA201000611A1 (ru) | 4,4-дизамещенные пиперидины |